Header
Menü schließen
Merken
Figure 1
Biopharmaceuticals: Benefits for Patients with Autoimmune Diseases
Targeted therapy, smart devices and patient support programs ensure patient well-being and additionally benefit society at large
Arzneimittelwesen
Immunological drugs lead the German biopharmaceutical market
Understanding autoimmune diseases
Combating autoimmune diseases with biopharmaceuticals
Advances in medical devices aid therapy success
Patient support programs lead to lower dropout rates
Biopharmaceuticals benefit patient well-being and society
Biopharmaceuticals are indispensable for treating autoimmune diseases
Understanding autoimmune diseases
Combating autoimmune diseases with biopharmaceuticals
Advances in medical devices aid therapy success
Patient support programs lead to lower dropout rates
Biopharmaceuticals benefit patient well-being and society
Biopharmaceuticals are indispensable for treating autoimmune diseases
Dr. Frank Mathias1 and Dr. Latika Bhonsle-Deeng2 · 1 Rentschler Biopharma SE, Laupheim and · vfa bio, Berlin 2 · Rentschler Biopharma SE, Laupheim
 | Dr. Frank Mathias has more than 25 years’ experience in leading positions in the pharma and biotech industry. He studied pharmacy at the Paris VI University, receiving a PhD in 1991. After working as International Product Manager at Hoechst AG, he took over as General Manager of Servier Deutschland, and then Amgen GmbH. Following that, he was CEO of Medigene AG. Moreover, he is Chairman of vfa bio, which represents biotech interests within the German Association of Research-Based Pharma Companies. Since |
